Linoleyl carbonate-paclitaxel conjugate - Luitpold Pharmaceuticals

Drug Profile

Linoleyl carbonate-paclitaxel conjugate - Luitpold Pharmaceuticals

Alternative Names: 2-linoleyl carbonate-paclitaxel; LOC-pac; LOC-paclitaxel

Latest Information Update: 17 Jun 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Luitpold Pharmaceuticals
  • Developer Luitpold Pharmaceuticals; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Diterpenes; Paclitaxels; Small molecules; Taxanes
  • Mechanism of Action Mitosis inhibitors; Platelet-derived growth factor inhibitors; Proto-oncogene protein c-bcl-2 inhibitors; Tubulin inhibitors; Tubulin polymerisation promoters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Malignant melanoma

Most Recent Events

  • 01 Feb 2016 Luitpold Pharmaceuticals terminates a phase I trial in Malignant melanoma (Metastatic disease, Second-line therapy or greater) in USA due to early positive results (NCT01039844)
  • 30 May 2013 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top